Clinical and Radiological Outcomes in People with Aquaporin-4 IgG Positive Neuromyelitis Optica Spectrum Disorder Following Ravulizumab Treatment (AMAZE) (P7-8.018)
To prospectively study the clinical performance of ravulizumab, enhance knowledge on conventional MRI outcomes, assess for occult disease activity via contemporary imaging metrics, identify serum biomarkers related to disease progression, and to explore contemporary social factors that may impact neurological outcomes in people with neuromyelitis optica spectrum disorder (NMOSD).
Authors
- Darin T. Okuda (ORCID: https://orcid.org/0000-0002-6499-1523)
- Tatum M. Moog (ORCID: https://orcid.org/0000-0002-1407-8621)
- Marco C. Pinho (ORCID: https://orcid.org/0000-0002-4645-1638)
- Jeannette N. Stankowski (ORCID: https://orcid.org/0000-0002-8481-2940)
- Katy W. Burgess
- Peter V. Sguigna (ORCID: https://orcid.org/0000-0003-1825-575X)
- Madhukar S. Patel (ORCID: https://orcid.org/0000-0001-7508-899X)
- Aksel Sıva (ORCID: https://orcid.org/0000-0002-8340-6641)
- Gabriel Pardo (ORCID: https://orcid.org/0000-0002-2207-3708)
- Christine Lebrun‐Frénay (ORCID: https://orcid.org/0000-0002-3713-2416)
- Morgan McCreary (ORCID: https://orcid.org/0000-0002-8378-460X)
- Fang Yu (ORCID: https://orcid.org/0000-0001-9913-1331)
- Tom G. Punnen
Institutions
- Oklahoma Medical Research Foundation (US)
- Istanbul University-Cerrahpaşa (TR)
- Neurology, Inc (US)
- Alexion Pharma (Switzerland) (CH)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211767
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00